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 3 
Summary 4 
 5 
The mechanistic details of the pathogenesis of Chlamydia, an obligate intracellular pathogen 6 
of global importance, have eluded scientists due to the scarcity of traditional molecular 7 
genetic tools to investigate this organism. Here we report a chemical biology strategy that has 8 
uncovered the first essential protease for this organism. Identification and application of a 9 
unique CtHtrA inhibitor (JO146) to cultures of Chlamydia resulted in a complete loss of 10 
viable elementary body formation. JO146 treatment during the replicative phase of 11 
development resulted in a loss of Chlamydia cell morphology, diminishing inclusion size, and 12 
ultimate loss of inclusions from the host cells. This completely prevented the formation of 13 
viable Chlamydia elementary bodies. In addition to its effect on the human C. trachomatis 14 
strain, JO146 inhibited the viability of the mouse strain, Chlamydia muridarum, both in vitro 15 
and in vivo. Thus, we report a chemical biology approach to establish an essential role for 16 
Chlamydia CtHtrA. The function of CtHtrA for Chlamydia appears to be essential for 17 
maintenance of cell morphology during replicative the phase and these findings provide proof 18 
of concept that proteases can be targetted for anti-microbial therapy for intracellular 19 
pathogens.  20 
 21 
 22 
23 
Introduction 1 
Chlamydia are obligate intracellular bacterial pathogens with significant clinical importance. 2 
Chlamydia (C.) trachomatis is the most common sexually transmitted bacterial infection 3 
world wide and the occular infecting serovars are the most common cause of preventable 4 
blindness worldwide (WHO, 2011). In spite of the substantial health burden due to the 5 
Chlamydia, comparatively little is known about the organism’s functional pathogenesis and 6 
disease mechanisms.  7 
Members of the chlamydiae family are distinguished by an unusual bi-phasic 8 
developmental cycle that consists of a small, tough, spore-like, non-replicative extracellular 9 
form (termed the elementary body (EB)) and the intracellular replicative, metabolically 10 
active, non-infectious form (called the reticulate body (RB)). The intracellular phase occurs 11 
exclusively in a unique vacuole known as the inclusion vacuole (reviewed (Abelrahman & 12 
Belland, 2005)). This developmental cycle and the obligate intracellular nature of the 13 
Chlamydia have hampered efforts to develop traditional techniques to genetically manipulate 14 
the organism. Although there have been recent developments, including a chemical mutation 15 
approach to generate chromosomal mutants (Kari et al., 2011) and successful transformation 16 
of the organism with its own plasmid (Wang et al., 2011),  biological understanding of this 17 
organism remains limited relative to its economic and health impact.  18 
The highly conserved protease HtrA (Chlamydia HtrA; CtHtrA) has been described as 19 
having a number of virulence functions in pathogenic bacteria (Chitlaru et al., 2011, Hoy et 20 
al., 2010). This protease has also been described in C. trachomatis using in vitro and 21 
microscopy methods, and in Chlamydia it potentially functions as both a bacterial cell 22 
associated protease and as a secreted virulence factor (from 28 hours post infection) (Huston 23 
et al., 2007, Huston et al., 2008, Wu et al., 2011). Our previous investigations into the 24 
biochemical mechanism of activation implicated outer membrane protein sequences with 1 
activation of the chaperone form, suggesting a potential role in surface protein assembly 2 
(Huston et al., 2011). Recently the protease that has been considered to be the major 3 
chlamydial pathogenesis factor, (CPAF), has been the focus of controversy as it appears that 4 
many of the functions attributed to this protease may have been detected as an artefact of the 5 
sample preparation (Chen et al., 2012), including a key function thought to be critical for 6 
viable infectious yield  (Heuer et al., 2009).  7 
Other chlamydial virulence factors have also been uncovered using small molecule 8 
approaches, including the bacterial type III protein secretion inhibitor (Wolf et al., 2006), and 9 
a peptidomimetic to the type III secretion ATPase protein interaction domain (Stone et al., 10 
2011). These studies support the fact that chemical approaches are a powerful strategy to 11 
investigate the function of proteins within this unique organism. Here we screened for and 12 
found a novel selective inhibitor against a CtHtrA. Using this protease inhibitor, JO146, we 13 
demonstrated an essential role for CtHtrA for chlamydial developmental cycle progression 14 
during the replicative phase. JO146 treatment resulted in chlamydial cell morphology loss, 15 
the reduction in inclusion vacuoles and eventual complete bacterial lethality as the result of 16 
failure to develop viable infectious progeny (EBs). 17 
 18 
Results 19 
Selective and specific phosphonate inhibitors of CtHtrA are lethal to C. trachomatis when 20 
added during the replicative phase of the developmental cycle  21 
A library of 1090 serine protease inhibitors (previously described (Arastu-Kapur et al., 2008, 22 
Hall et al., 2011)) was screened against CtHtrA in vitro protease activity (detailed in the 23 
Experimental Procedures). An initial screen identified two inhibitors, JO146 and JCP83 1 
(IC50s: 12.5 M and 47.19 M, Fig 1A). Both are peptides with a C-terminal phosphonate 2 
‘warhead’ electrophile which reacts irreversibly with the protease active site serine residue 3 
(Oleksyszyn & Powers, 1991) (Jackson et al., 1998), and differ only in the P3 position 4 
(Val/Ala). Both inhibitors have valine at the P1 position and proline at P2. The two inhibitors 5 
were quite selective towards CtHtrA when screened against a series of other serine and HtrA 6 
family proteases (Table 1, Fig. S1). Inhibition was only observed for HTRA2 and elastase. 7 
Neither compound was cytotoxic to McCoy and HEp-2 cells, both common cell lines used for 8 
Chlamydia culture. Specifically, we detected no cell lysis or impaired metabolic turnover 9 
when the cells were incubated with JO146 or JCP83 for 8 h (Table S1, as described in the 10 
supporting data).  11 
The two inhibitors were added to C. trachomatis HEp-2 cultures at different time 12 
points throughout the developmental cycle (Fig. 1B: lag ~8h, replication at ~2.4 h per 13 
division, EB formation from ~24 h post infection (h PI) (Miyairi et al., 2006)). Viable 14 
infectious elementary bodies (inclusion forming units) at completion of the developmental 15 
cycle after each of these independent treatments was then determined. As shown in Fig. 1C-16 
F, addition of JO146 or JCP83 resulted in complete or significant (p<0.001) loss of viable 17 
elementary body formation when added during the replicative phase. The activity was most 18 
effective at higher doses, however, at 16 h PI even 10 M JO146 had a significant impact on 19 
viability with a lower Chlamydia multiplicity of infection (MOI) (Fig. 1C, p<0.001). The host 20 
cell numbers were the same under each condition so these data indicate that the amount of 21 
Chlamydia present (MOI) associates with the effectiveness of the compounds. 22 
 23 
The lethality of JO146 for C. trachomatis at 16 h PI does not require host cell protein 1 
synthesis, and is not influenced by the type of host cell  2 
Chlamydia viable yield from cell culture improves when a host cell protein synthesis 3 
inhibitor (cycloheximide) is used (Thomas et al., 1977). We tested the role of host cell 4 
protein synthesis during JO146 inhibition (16 h PI) at an MOI of 0.3 in HEp-2 cells. The 5 
lethality of JO146 was determined at 44 h PI and was found to be maintained in the presence 6 
of cycloheximide (Fig. 2A).  7 
C. trachomatis is capable of infection and replication within a variety of epithelial 8 
cells. The effectiveness of JO146 against C. trachomatis when added at 16 h PI was 9 
evaluated in a variety of host cell types with viability determined at 44 h PI (MOI 0.3). There 10 
were different yields of C. trachomatis depending on the host cell type infected which was 11 
expected (Fig. 2B). There were significantly (p<0.001) higher yields of viable Chlamydia 12 
when cultured in McCoy cells; however JO146 was still lethal for C. trachomatis at a 13 
concentration of 100 M in McCoy cells. These data suggest that JO146 activity is dependent 14 
on the amount of Chlamydia present, that it does not require host cell protein synthesis and 15 
that inhibitor activity is not dependent on the host cell type. 16 
 17 
A JO146 activity based probe labels CtHtrA  18 
We synthesised an activity-based probe based on the JO146 structure in which a Cy5 dye was 19 
attached in place of the Boc protecting group on the parent compound. We then monitored 20 
labelling of targets throughout the C. trachomatis developmental cycle (Fig. 3A, B). Three 21 
predominant labelled proteins were observed with one additional weakly labelled species. A 22 
dominant doublet of proteins around 48-50 kDa were labelled by JO146-Cy5 throughout the 23 
developmental cycle (Fig. 3B). These labelled proteins are consistent with the banding 1 
pattern and molecular weight of CtHtrA as observed by western blot(Fig. 3B), and as 2 
consistent with previous reports using alternate antibodies (Wu et al., 2011). The high levels 3 
of CtHtrA present at time zero, or in the elementary bodies, do not show corresponding high 4 
levels of binding of JO146 as it is unlikely that the compound can enter this cellular form of 5 
Chlamydia. The next most intensely labelled band was at approximately 37 kDa. Two 6 
additional, less intensely labelled bands were detected at approximately 25 kDa and 125 kDa 7 
(Fig. 3B).  8 
We conducted competitive binding assays to confirm that the JO146-Cy5 activity-9 
based probe bound to the same targets as JO146. C. trachomatis infected and uninfected 10 
HEp-2 cells were harvested at 22 h PI and a titration of JO146 was added to either lysed or 11 
unlysed cell cultures. JO146-Cy5 was added 30 minutes later. The same proteins previously 12 
observed in Fig. 3A were also observed (lane 1, Fig. 3C). The binding of JO146-Cy5 to all of 13 
the proteins except the ~25 kDa species was competitively inhibited by JO146 pre-incubation 14 
(Fig. 3C). The ~25, ~37 and ~125 kDa proteins were also present in the HEp-2 only cultures. 15 
Thus, JO146 appears to bind to two mammalian proteins (~125 kDa and ~37 kDa) and to a 16 
doublet of proteins corresponding to CtHtrA. CtHtrA JO146-Cy5 binding was competitively 17 
inhibited by the addition of JO146 to live, unlysed cultures supporting the compound entering 18 
the inclusion vacuole as CtHtrA is only detected inside the inclusion at this time point (Wu et 19 
al., 2011).  20 
A JO146-Biotin activity-based probe was used to isolate the labelled proteins and 21 
confirm their identities by proteomics. Purified recombinant CtHtrA was incubated with the 22 
JO146-Biotin activity-based probed and streptavidin-magnetic bead binding was used to 23 
confirm that CtHtrA can be isolated using this methodology, and therefore that this activity-24 
based probe binds to CtHtrA (Supporting data Fig. S2). We then applied this approach to 25 
chlamydial cell culture lysates to identify proteins labelled by JO146-Biotin. The experiment 1 
was conducted at 24 h PI to maximise the yield of chlamydial material present and included 2 
controls of HEp-2 lysates only and C. trachomatis infected HEp-2 lysate without JO146-3 
Biotin. In the experiment where JO146-biotin was isolated from a C. trachomatis infected 4 
HEp-2 lysate we observed clumping and aggregation. This may suggest that when we are 5 
binding and isolating CtHtrA from a lysate, proteins which are bound by CtHtrA are also 6 
isolated (potentially specific or non-specific substrates). We have previously demonstrated 7 
that CtHtrA is a chaperone and protease that can form large oligomeric cages to chaperone 8 
substrates (Huston et al., 2011). Therefore, it is likely that, under cell lysis conditions, CtHtrA 9 
binds to many proteins which may not necessarily be specific substrates. Accordingly, several 10 
proteins were observed to be isolated by the JO146-biotin activity-based probe streptavidin 11 
isolation which did not correspond to the proteins previously detected to be bound by JO146-12 
Cy5 in Fig. 3 (see Fig. 4). CtHtrA was identified by mass spectrometry (as described in 13 
Experimental Procedures) (~48 kDa) as the only band which corresponds to this molecular 14 
mass with two peptides identified which correspond to CtHtrA (Mascot Score 104, 15 
significance threshold p<0.0005). Interestingly, we also identified the chlamydial protein 16 
MOMP (major outer membrane protein) by mass spectrometry as the 37 kDa band (Mascot 17 
score 166, 5 peptides, significance threshold p<0.0005), however it is possible that this is a 18 
post-lysis artefact of CtHtrA binding rather than a genuine CtHtrA substrate or JO146-Biotin 19 
target. Two host cell proteins (Myosin-9 and DHX9) were also present in the JO146-biotin 20 
pull down (and not the negative controls), however, as suggested for MOMP it is also 21 
possible that these are pulled down by CtHtrA (possible artefact given the protein binding 22 
capacity of CtHtrA) rather than being direct JO146-biotin or CtHtrA substrates (Fig. 4). 23 
Regardless, these results confirm that JO146-biotin binds to CtHtrA in a cell culture lysate. 24 
 25 
The lethality of JO146 treatment relates to the timing of the chlamydial developmental 1 
cycle timing 2 
The observed requirement of JO146 addition to be at 16 h PI for complete lethality may be a 3 
consequence of the phase of chlamydial growth (i.e. replicative phase), or alternatively may 4 
reflect a short term stability of the compound. Hence, we conducted further investigations by 5 
firstly, removing the compound during the culture experiments, and secondly extended 6 
culturing prior to determining viable infectious yield. JO146 was added to cultures at 16 h PI 7 
in an identical experiment to that shown in Fig. 1. JO146 was removed from the cultures by 8 
extensive washing at 20 and 24 h PI and chlamydial viability was determined at 44, 54, and 9 
64 h PI. JO146 treatment at 16 h PI was lethal for chlamydial viability, even after extended 10 
culturing until 54 and 64 h PI (consistent with the fig 1 data where viability was measured at 11 
44 h PI; see Fig. 5A). JO146 treatment was still highly effective but not completely lethal 12 
when washed out after 4 and 8 h after treatment (20 and 24 h PI respectively) with 1-2 log 13 
reduction in viability (Fig. 5B & C). The loss of viability when the compound was washed 14 
out 4 and 8 h after addition was partially rescued (~0.5 log) by extended culture in the 15 
absence of the compound (to 54 and 64 h PI) (Fig. 5B & C). To further explore the 16 
developmental cycle time point dependency of JO146 lethality, treatments of either isolated 17 
chlamydial EBs or host cells prior to commencing the infection was tested. In these 18 
experiments, some reduction in viability was observed with the host cell JO146 treatment 19 
prior to infection (~1 log; Supporting data Fig. S3).   20 
We tested the compound’s stability during the mid-developmental cycle conditions 21 
where lethality was observed, by monitoring the in vitro stability of the JO146-Cy5 activity-22 
based probe. The probe was added to cell culture lysates (16 h PI) cultured under identical 23 
conditions as used for the experiment shown in Fig. 1. The cultures were then incubated for 4 24 
and 8 h (37°C, 5% CO2) under the standard culture conditions and the lysates were harvested 25 
and examined by SDS-PAGE to monitor JO146-Cy5 labelling. The JO146-Cy5 was stable 1 
throughout this experiment (Fig. 5D), suggesting that the critical nature of the timing of 2 
compound addition for maximum effectiveness related specifically to a developmental cycle 3 
feature of Chlamydia rather than compound stability.  4 
 5 
JO146 treatment results in diminishing chlamydial inclusion vacuole size and eventual loss 6 
of inclusions over time in cell culture  7 
We monitored inclusion vacuole size in real time using wide field microscopy after JO146 8 
was added to HEp-2 C. trachomatis cultures at 16 h PI. The inclusions appear as non-stained 9 
or dark areas inside the cells which in control cultures (DMSO or media)increased in size 10 
over time (Fig. 6, and Video S1). In contrast, during JO146 treatment, the inclusions 11 
appeared to diminish in size and eventually could not be visualised (Fig. 6A). This was 12 
quantified by measuring inclusion vacuole size and number of inclusion vacuoles present 13 
confirming that the inclusions decrease in size and number during JO146 treatment (Fig. 6B-14 
C). No significant difference was detected between DMSO and JO146 treatments for number 15 
of host cells present or lost throughout the entire duration of the video (Supporting data, Fig. 16 
S4).  17 
 18 
Confocal microscopy shows that JO146 treatment results in decreasing inclusion size and 19 
loss of chlamydial cellular morphology  20 
The apparent diminishing size and eventual loss of inclusions from the cultures observed by 21 
real time microscopy was further examined using immunocytochemistry and confocal laser 22 
scanning microscopy. Cultures (MOI 0.3) were fixed and labelled for MOMP, -actin 23 
(phalloidin) and nucleus (DAPI) and examined at a series of time points following JO146 1 
addition at 16 h PI. Representative images are shown in Fig. 7A-E. The inclusions are much 2 
smaller at 24 h PI when treated with JO146 compared to the DMSO controls (Fig. 7F), and 3 
there are fewer chlamydial cells within the inclusions. In some cases no discernable cell 4 
shapes are apparent compared to the robust inclusion observed in the DMSO treated controls. 5 
The same observations were made when the Chlamydia were stained using anti-HtrA 6 
antibodies and measured either by Deltavision or Confocal Microscopy (Supporting data, Fig. 7 
S5 and S6). Similar observations were made when the cultures were examined using super 8 
resolution microscopy (outlined in the supporting data results section and Fig. S7).  9 
This observation of chlamydial inclusion development failure was further investigated 10 
by measuring EB formation over time in the presence of JO146. JO146 treatment at 16 h PI 11 
completely prevented the development of viable elementary bodies at all time points at which 12 
EBs were detected in the controls (p<0.001; Fig. 7G). This was also consistent with an 13 
observed loss of the chlamydial proteins MOMP and CtHtrA without any impact on host -14 
actin levels over the same time course (Supporting data Fig. S8). Viability of the host cells 15 
was monitored using a Live/Dead fixable flow cytometry assay for the same time points and 16 
there was no significant difference in numbers of dead host cells between JO146 (100 M) 17 
treated and DMSO controls (Supporting data, Table S2 and Fig. S9).  18 
Immunofluorescence for MOMP with LAMP1 (late endosome), or SQSTM1 19 
(sequestosome) was conducted at 20 and 24 h PI after JO146 addition (at 16 h PI) to 20 
determine if either of the host proteins interacted directly with the JO146-treated inclusions. 21 
Additionally live monitoring of lysosome staining using lysotracker was also conducted at 20 22 
and 24 h PI after JO146 addition (at 16 h PI). We observed no recruitment of lysosomes, or 23 
the makers SQSTM1 or LAMP1 to the chlamydial inclusion regardless of treatment 1 
conditions (JO146 or DMSO) (Supporting data, Fig. S10).   2 
 3 
JO146 is effective in vivo using the mouse C. muridarum model of disease  4 
The effectiveness of JO146 treatment in vivo was evaluated using the C. muridarum mouse 5 
model of genital tract infection. JO146 and JCP83 inhibited CmHtrA during in vitro assays, 6 
although with reduced potency compared to CtHtrA (Table 1). JO146 and JCP83 treatment of 7 
C. muridarum infections in in vitro mouse cell culture (McCoy cells) led to a ~2-~2.5 log 8 
reduction in viable infectious yield of elementary bodies, with JO146 being slightly more 9 
effective (Fig. 8A-B). The C. muridarum developmental cycle is complete within 26-30 h, 10 
and again the most effective time (12 h PI) for JO146 treatment was consistent with the 11 
replicative phase. Similar reduced viability was observed against C. muridarum when the 12 
compounds were tested using a different host cell (HEp-2) (p<0.001; Supporting data, Fig. 13 
S11).  14 
The impact of vaginal treatment with 50 mg/kg of JO146 every second day for 14 15 
days on uninfected mice and on the progression of a vaginal C. muridarum infection was 16 
investigated. No toxicity was detected from JO146 treatment of uninfected mice (described in 17 
the supporting items). C. muridarum genital infections of progesterone synchronised female 18 
BALB/C mice were tested by treating the mice every second day of infection with vaginal 19 
administration of DMSO, or 50 mg/kg JO146. Vaginal swabs were collected every third day 20 
and the amount of viable Chlamydia shed from the genital tract was determined (Fig. 8C). In 21 
this experiment which involved only six mice, there was a small but statistically significant 22 
reduction (p<0.05) in the total viable Chlamydia shed from 50 mg/kg JO146 treatments 23 
compared to DMSO control.  24 
 1 
 2 
Discussion 3 
A chemical approach to inhibit the serine protease CtHtrA during the chlamydial 4 
developmental cycle in human cell culture has demonstrated complete lethality for C. 5 
trachomatis. Specifically, treatment of cultures during the replicative phase with a CtHtrA 6 
protease inhibitor (JO146) led to lethality with no viable elementary bodies detected. This 7 
coincided with a loss of chlamydial cell morphology, diminishing inclusion size, and eventual 8 
loss of detectable inclusions in the cultures. The lethality occurred independently of the host 9 
cell type, host cell protein synthesis, in the absence of any host cell toxicity or death, or any 10 
activation of the major pathogen protection pathways (lysosome or autophagy).  11 
The compounds were identified by screening a library of serine protease inhibitor 12 
compounds using our previously established CtHtrA protease assay (Huston et al., 2011). The 13 
library consisted of a collection of various electrophillic molecules that form a covalent bond 14 
with the active site serine of serine proteases and hydrolyases. The screen identified two 15 
compounds (JO146 and JCP83) from two distinct synthetic sources with similar peptide 16 
sequences and identical primary electrophiles. When screened against a variety of proteases 17 
in vitro, the compounds were found to be selective towards CtHtrA. It is important to note 18 
that the activity of JCP83 and JO146 in vitro against protein substrates was not as effective as 19 
the in vivo activity observed against Chlamydia. It is not clear why this may be the case, 20 
although the in vitro substrates used were model proteins and not known substrates. JO146 21 
and JCP83 were lethal against Chlamydia when added during the replicative phase of the 22 
chlamydial developmental cycle. JO146 has a lower IC50 value compared to JCP83 from the 23 
protease assays and was also more effective on the in vitro cultures. Several observations 24 
suggested a chlamydial target protein was required for the lethality of this compound. The 1 
lethal impact of JO146 was not associated with any host cellular toxicity or cell death. This 2 
lethality was impacted directly by the multiplicity of infection (amount of Chlamydia present 3 
in the cultures), did not require active host cell protein synthesis, and was independent of the 4 
host cell type. Although other studies have resulted in several log reductions in viability 5 
(Christian et al., 2011, Stone et al., 2011), this is the first time that any small molecule or 6 
inhibitor strategy has resulted in complete lethality to Chlamydia. There is another 7 
chlamydial protease (CPAF, chlamydial secreted protease activity factor) that may also be a 8 
critical factor for chlamydial growth. CPAF has been identified as an important protease 9 
target for intracellular impairment of chlamydial growth. The authors used a caspase-1 10 
inhibitor (WEHD-fmk) that had previously been shown to inhibit the in vitro CPAF protease 11 
activity and demonstrated a 10-fold reduction in viable chlamydial yield when this compound 12 
was added at 24 h PI (Christian et al., 2011). The validation of this inhibitor acting directly 13 
via binding to CPAF was the presence of golgin-84 cleavage (Christian et al., 2011). 14 
However, subsequent to this publication, concerns have been raised about the role of CPAF 15 
during cell culture due to the experimental methods utilised. In particular, recent work 16 
determined that goglin-84 fragmentation may be an artefact of the chosen experimental 17 
design (Chen et al., 2012). Therefore, it remains unclear if CPAF is an important protease for 18 
Chlamydia.     19 
The timing of compound addition during the chlamydial developmental cycle had a 20 
significant impact on the effectiveness of JO146 treatment. JO146 was most effective when 21 
added at 16 h PI, consistent with an effect on the middle of the chlamydial replicative phase 22 
of development. JO146 was lethal when added at 16 h PI at all concentrations above 10 M. 23 
A dose of 50 M resulted in a 1-2 log reduction in yield when added at 6, 20 or 24 h PI, but 24 
was completely lethal at 16 h PI. While we know the chlamydial developmental cycle is 25 
asynchronous, the completion of replication by binary fission is quite rapid. Miyairi and co-1 
workers comprehensively characterised the parameters of replication and EB formation for a 2 
number of serovars and found that for serovar D, logarithmic replication occurs from 3 
approximately 12-24 h PI with a marked halt of replication from approximately 24 h PI 4 
onwards (Miyairi et al., 2006). EB formation could be detected from approximately 20 h PI 5 
onwards and gradually increased until approximately 40 h PI (Miyairi et al., 2006). 6 
Therefore, EB formation is highly asynchronous; however the replicative phase is tightly 7 
defined as between 12 and 24 hr PI. The data presented here strongly suggests that JO146 is 8 
only effective on chlamydial cells that are actively replicating or transitioning to EBs, as prior 9 
treatment of EBs (Fig. S2) or treatment late during the developmental cycle was not effective. 10 
The compound was most effective at 16 h PI, exactly mid-replicative phase, at 12 h PI not all 11 
cells will be replicating and after 24 h PI a significant proportion of the cells will be 12 
beginning to transition back to elementary bodies. The removal of JO146 at 24 h PI (8 h after 13 
administered) showed a 2.5 log reduction in viability indicating that the most effective phase 14 
of inhibition was throughout the replicative phase until EB formation. There may be some 15 
other ‘off-target’ impacts on the host cell which could explain the 0.5-1 log reductions in 16 
viability observed when JO146 was added early during the developmental cycle (8 h PI) or 17 
when some loss of viability was observed during host cell pre-treatment (Supplementary data 18 
Fig. S2). However, only the 16 h PI treatment was lethal suggesting that the major impact of 19 
JO146 is specific to Chlamydia. Therefore, these data indicate that JO146 is inhibiting a 20 
specific function involved in replication that is essential for Chlamydia. Interestingly, with 21 
extended cultures (54 and 64 h PI) and following removal of the compound at 24 h PI, there 22 
was some rescue of viability indicating that the compound may be partially inducing 23 
chlamydial persistence (Fig. 5). HtrA has been described as a protease and chaperone with 24 
broad roles in protein maintenance and stress response in many bacteria (Clausen et al., 25 
2011). For some bacteria, substrates of HtrA are essential for viability and pathogenesis of 1 
the organism. Perhaps the best described example of this is the Shigella protein IcsA, which 2 
requires HtrA/DegP for its correct assembly. In the absence of HtrA Shigella does not 3 
correctly present IcsA on the surface of the cell, resulting in the inability to generate actin 4 
tails and virulence attenuation (Purdy et al., 2007). The mechanism of chlamydial death 5 
observed during this study was unique, with loss of chlamydial cell structure within the 6 
inclusion as well as diminishing the chlamydial inclusion size with eventual loss of any 7 
detectable inclusions. This correlated with a loss of viable elementary bodies. This 8 
chlamydial death and inclusion loss appeared to relate directly to the observed Chlamydia 9 
defects and not a host mediated mechanism. Thus, it appears that addition of a CtHtrA 10 
inhibitor during the replicative phase of C. trachomatis disrupts the chlamydial 11 
developmental cycle, by impacting reticulate body cellular morphology, resulting in the 12 
reduction in inclusion vacuole size, and ultimate loss of inclusions from the host cell without 13 
viable elementary body formation. 14 
The use of an activity-based probe strategy enabled direct assessment of compound 15 
selectivity. The targets of JO146 comprised a protein species corresponding to CtHtrA and 16 
two additional mammalian cell proteins. The labelled protein corresponding to CtHtrA was 17 
competitively inhibited by prior binding of JO146 during live cell culture, supporting that the 18 
compound is accessing the chlamydial inclusion as CtHtrA has only been detected inside the 19 
inclusion vacuole at this time point (Wu et al., 2011). A biotin activity-based probe was used 20 
in an affinity purification experiment which further validated that JO146 binds to CtHtrA. 21 
These experiments represent the first use of an activity-based probe strategy for any protein 22 
within Chlamydia and provide key evidence that our lead compound JO146 preferentially 23 
binds CtHtrA.  24 
Regardless of the mechanism of chlamydial death, JO146 was also effective in vivo. 1 
JO146 vaginal administration during female mice genital tract infection significantly reduced 2 
the viability of C. muridarum. This in vivo effectiveness is an exciting finding supporting the 3 
concept that chemical strategies can be applied both to investigate the functional role of 4 
proteases in the unique biology of this organism, but can also be applied to demonstrate in 5 
vivo significance. This is the first report of an inhibitor or small molecule for Chlamydia that 6 
has been successfully applied in vivo to treat Chlamydia infection. Together, these findings 7 
demonstrate that CtHtrA is essential for Chlamydia replication and provides proof of concept 8 
that CtHtrA is a suitable candidate for future drug development.  9 
 10 
Experimental Procedures 11 
Protease activity, inhibitor screening, and synthesis  12 
Serine protease activity for CtHtrA was monitored using a previously described in vitro assay 13 
with the substrate (MCA-ENLHLPLPIIF-DNP) (Huston et al., 2011). A library of serine 14 
protease inhibitor compounds including isocoumarins, and peptides with various electrophiles 15 
was screened against CtHtrA activity and hits tested against other proteases. The screen was 16 
initially conducted using all compounds at a 500 M concentration, compounds which 17 
showed a complete loss of activity were selected and further screened at a series of 18 
concentrations to identify those most effective at lower concentrations in vitro. The top hits 19 
were validated for purity and structral integrity using mass spectrometry, this led to the 20 
selection of JO146 and JCP83 as the most effective compounds which were structurally intact 21 
and pure. The proteases tested included trypsin, chymotrypsin, elastase, and recombinant 22 
forms of HTRA1 (human), HTRA2 (human), Escherichia coli DegS and DegP, (using 23 
previously published assays (Merdanovic et al., 2010, Wilken et al., 2004)). JO146 [Boc-Val-24 
Pro-ValP(OPh2)], JO146-Biotin and JCP83 [Boc-Ala-Pro-ValP(OPh2)] were synthesised 1 
commercially using standard protocols when additional stocks were required (VCare, China). 2 
The activity-based probe JO146-Cy5 was synthesised from JO146 by first acidic removal of 3 
the tert-butyloxycarbonyl group using a 1/1 mixture of dichloromethane and trifluoroacetic 4 
acid for 30 minutes at room temperature. After concentration in vacuo, the resulting free N-5 
terminus was capped with 1 molar equivalent of Cy5-N-hydroxysuccinimide ester and 5 6 
equivalents of N,N-diisopropylethylamine in DMSO for 1 hr to give JO146-Cy5 after HPLC 7 
purification. MS (ESI): m/z 570.9 [½(2M+H)]+, 1140.8 [M]+. 8 
 9 
Chlamydia culture 10 
Chlamydia trachomatis serovar D/UW-3/Cx  was routinely cultured in HEp-2 cells on 11 
DMEM, 10% Fetal calf serum (heat-inactivated serum was used) media, at 37°C 5% CO2.  12 
Chlamydia muridarum strain Weiss was routinely cultured in McCoy cells (McCoy B) on 13 
DMEM, 10% fetal calf serum, at 37°C, 5% CO2. Ecc1 (an endometrial cancer cell line), and 14 
BEAS2b (a human lung epithelial cell line) were cultured on the DMEM, 10% FCS, at 37°C 15 
5% CO2. Inhibitor experiments were routinely conducted in 48 well plates seeded with 20000 16 
host cells per well 24 hours prior to the Chlamdyia infection. Cycloheximide was not added 17 
to any experiments except that in Fig. 2A (1 g/ml). The viable infectious yield was 18 
determined from cultures harvested at the completion of the developmental cycle during 19 
which inhibitor treatment was conducted (time of harvest is indicated on the figure). The 20 
cultures harvested in SPG were serially diluted and cultured in fresh HEp-2 monolayers at 30 21 
h PI the cultures were fixed and stained for microscopy. The number of inclusions visible at 22 
30 h PI was then determined by counting inclusions from at least 8 representative fields of 23 
view in triplicate wells for each serial dilution (with less than 80% infected host cells only 24 
considered valid) and extrapolating the field of view size to the size of wells to calculate the 1 
total number of inclusions in the well, dilutions and volumes added to the wells were then 2 
accounted for to give the viable IFU/ml. Quantitative analysis of viability and morphological 3 
properties was conducted using GraphPad Prism, statistical analysis was routinely conducted 4 
usign 2-way Anova and Bonferroni post-tests (typically relative to the DMSO control). 5 
 6 
Microscopy 7 
C. trachomatis cultures were examined using immunofluorescence using the Leica SP5 8 
Confocal microscope with antibodies against CtHtrA, MOMP (Biodesign), LAMP-1 9 
(AbChem), and SQSTM1 (AbCam), and secondary antibodies conjugated to Alexafluor dyes 10 
(Invitrogen) (Huston et al., 2008). Live cell imaging was performed using a Leica AF6000 11 
widefield microscope. The CellTracker concentration was optimised so that it did not 12 
penetrate the chlamydial inclusion. 1 M CellTracker (Invitrogen) was added to cultures 13 
grown in glass-bottomed, chamber-welled slides 45 mins before JO146 addition. Images 14 
were constructed using the Leica application suite. Where indicated immunofluorescence was 15 
also monitored using a Deltavision (personal DV deconvolution microscope) (Applied 16 
Precision Inc, Issaquah, WA). 3D structured illumination microscopy (3D-SIM) of the 17 
Chlamydia inclusions was conducted using a Deltavision OMX OMX Imaging Sytem with 18 
Blaze module as previously described (Strauss et al., 2012). Raw images were processed and 19 
reconstructed as previously described (Schermelleh et al., 2008, Gustafsson et al., 2008).  20 
 21 
Activity gels, immunoblots, and PAGE 22 
Activity-based probe binding activity in cell culture and cell lysates was monitored using 1 
polyacrylamide gel electrophoresis and scanning of the gels using the Li-Cor Odyssey at 2 
700nm. Activity-based probe binding was conducted on cultures from T25 flasks at different 3 
time points, whilst the competitive binding assays were conducted on cultures from T80 4 
flasks harvested at 22 h PI. Western blots for CtHtrA and MOMP were conducted as 5 
previously described (Huston et al., 2008).  6 
 7 
Affinity purification and proteomics 8 
JO146-biotin was used for affinity purification experiments. Streptavidin Dynabeads 9 
(Invitrogen, Australia) were used to affinity purify JO146-biotin from cell culture lysates in 10 
accordance with the manufacturers instructions. Cells were harvested, washed and then 11 
suspended in RIPA buffer (Peirce, Australia) and incubated on a turn wheel at room 12 
temperature for one hour to lyse the cells. Debri and unlysed cells were removed from the 13 
suspension by centrifugation at 10 000 × g for 10 mins. JO146-Biotin or DMSO was added to 14 
the lysates and incubated on a turn wheel at room temperature for 30 mins prior to addition of 15 
streptavidin Dynabeads. The samples were harvested using a magnetic block to allow buffer 16 
changes, 3 PBS washes and 4 PBST washes were conducted prior to elution of bound 17 
products from the beads using 0.1% SDS and boiling. Samples were analysed by SDS PAGE 18 
prior to gel excision for proteomics.  19 
Gel excised bands were then analysed by the Australian Proteomics Analytical 20 
Facility. Gel slices were cut up, washed and dried prior to rehydration with 100 ng of trypsin 21 
in 25 mM ammonium bicarbonate. After an overnight digestion at 37 Ԩ, peptides were 22 
extracted twice with a solution containing 50% acetonitrile and 5% formic acid. The sample 23 
was then concentrated on a peptide trap column, prior to LC and in-line mass spectrometry.  24 
LC eluent was subject to positive ion nanoflow electrospray MS analysis in an information 1 
dependant acquisition mode (IDA). In the IDA mode a TOFMS survey scan was acquired 2 
(m/z 350-1200, 0.5 second), with ten largest multiply charged ions (counts >150) in the 3 
survey scan sequentially subjected to MS/MS analysis.  MS/MS spectra were accumulated 4 
for 100 milli-seconds (m/z 100-1500) with rolling collision energy (ESI-QUAD-TOF). The 5 
peak lists of the LC/MS/MS data were generated using Analyst 2.0 MASCOT script and 6 
searched by Mascot against Human and Bacteria databases using MS/MS Ion 7 
search. Significance threshold for Human samples was (p<0.01), Bacterial samples 8 
(p<0.0005). This work was undertaken at APAF the infrastructure provided by the Australian 9 
Government through the National Collaborative Research Infrastructure Strategy (NCRIS). 10 
  11 
Animal model 12 
 All animal work must have been conducted according to the Australian Code of Practice for 13 
the Care and Use of Animals for Scientific Purposes, which has been embodied in the 14 
Queensland Animal Care and Protection Act 2001. The purpose of the Code is to ensure the 15 
humane care of animals used for scientific purposes, including teaching. QUT is accredited to 16 
conduct these activities. Animal ethics approval was granted from the QUT Animal Research 17 
Ethics Committee Approval number 1100000607. Female BALB/c mice provided by the 18 
Animal Resource Centre (Australia) were infected with 5 x 104 C. muridarum intravaginally. 19 
Methodology is described in the supplementary data.  20 
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 1 
Table 1. Specificity of inhibitor compounds, IC50 of compounds against a range of proteases 2 
 JO146 JCP83 
 Substrate 
Protease Peptide% ! Protein *# Peptide Protein 
CtHtrA 12.5 M (±2.94 
M) 
~200 M 47.19 M 
(±7.37 M)  
~500 M 
CmHtrA 47M (±7.19 
M) 
~100 M 93.69 M (± 
12.18  M) 
~400 M 
Chymotrypsin >500 M NA >500 M NA 
Trypsin >500 M NA >500 M NA 
Elastase 2.24 M (±0.12 
M) 
NA 0.310 M 
(±0.22 M) 
NA 
DegP >500 M >800 M > 500 M >800 M 
DegS NA >500 M  NA >500 M 
HTRA1 > 200  M >200  M  > 200  M ~200 M 
HTRA2 NA ~75 M  NA ~150 M 
% Peptide substrates were as follows; chymotrypsin: AAF-pNA (SigmaAldrich), 3 
trypsin: benzyl DL-R-pNA (SigmaAldrich), elastase: Nmethylsucc – AAPV-pNA 4 
(SigmaAldrich M4765), DegP: DPMFKLV-pNA, and HTRA1: (D-Arg)-(D-Arg)-5 
E(EDANS)-GKASPVAFP-K(Dab)-(D-Arg)-(D-Arg), CtHtrA/CmHtrA: MCA-6 
ENLHLPLPIIF-DNP. 7 
! IC50s for peptide substrates were determined by FRET or pNA assays with a range 8 
of concentrations of compounds. Data analysis conducted using GraphPad. 9 
* Protein based substrate IC50s were estimated from analysing the amount of protein 10 
substrate remaining after the assay using Coomassie stained PAGE. Protein substrates 11 
used were CtHtrA: -casein, CmHtrA: -casein, DegP: -casein, DegS: RseA (an 12 
activator peptide FFF-boc was included in this assay as required), HTRA1: Tau, 1 
HTRA2: -casein. 2 
NA: no substrate of this format is available for this protease 3 
 1 
Figure Legends 2 
Fig. 1. JCP83 and JO146 are lethal to Chlamydia at the replicative phase of the 3 
developmental cycle. (A) CtHtrA inhibitors JCP83 [Boc-Ala-Pro-ValP(OPh2)] and JO146 4 
[Boc-Val-Pro-ValP(OPh2)] identified during library screen. (B) The chlamydial 5 
developmental cycle and CtHtrA expression (Belland et al., 2003). (C-F) Viable infectious 6 
yield of C. trachomatis at the conclusion of the developmental cycle (44 h post infection 7 
(h PI)) is shown. HtrA inhibitors were added at different time points following the initial 8 
infection. (C) JO146 multiplicity of infection (MOI) 0.3, (D) JO146 MOI 3.0, (E) JCP83 9 
MOI 0.3, and (F) JCP83 MOI 3.0. The bars represent from left to right; white: DMSO 10 
control, gray: 0 M (media only), red: 10 M inhibitor, green: 50 M inhibitor, blue: 100 11 
M inhibitor, and yellow: 150 M inhibitor. ND: Note that the time 0 compound 12 
treatments with JCP83 were not conducted due to limited supply of this compound. The 13 
bars represent the mean from three independent experiments, error bars represent the SEM 14 
(n=6) * indicates p<0.05, ***p<0.001. 15 
 16 
Fig. 2. Host cell protein synthesis and host cell type do not influence the effectiveness of 17 
inhibition. (A) Viable infectious yield of C. trachomatis at 44 h PI following cycloheximide 18 
(black bars) addition to cultures prior to JO146 addition at 16 h PI (MOI 0.3). The white bars 19 
represent a control with no cycloheximide. (B) Viable infectious yield at 44 h PI of C. 20 
trachomatis cultured with different host cells treated with JO146 at 16 h PI. The bars 21 
represent the cell types McCoy, HEp-2, Ecc1, Beasb2b cells (left to right; MOI 0.3). The 22 
mean from three independent experiments with the standard error of the mean as error bars 23 
are shown on the graph (n= 27) * indicates p<0.05, ***p<0.001. 24 
 1 
Fig. 3. Activity-based probe confirms JO146 binds C. trachomatis proteins including a band 2 
at the size corresponding to CtHtrA. (A) JO146-Cy5 structure. (B) JO146-Cy5 (20 M) 3 
binding throughout the developmental cycle. CtHtrA and MOMP western blots on the 4 
samples are shown below the Cy5 scanned gel. Lanes represent time (h PI). (B) JO146 5 
(concentrations indicated above in µM) was added to lysed or unlysed cultures (upper and 6 
lower gels respectively) prior to lysis and binding with JO146-Cy5 (20 M). Lanes represent 7 
C. trachomatis infected HEp-2 cells treated with increasing concentrations of JO146 (1-5), 8 
uninfected HEp-2 cells with the same concentrations (6-10), purified recombinant CtHtrA 9 
(11), and purified recombinant S247A CtHtrA (active site serine mutant) (12).  10 
Corresponding CtHtrA immunoblots are shown below each gel.   11 
 12 
 13 
Fig. 4. JO146-Biotin Activity-based probe confirms JO146 is bound to CtHtrA. Samples 14 
from a dynabead-streptavidin pull down of JO146-biotin from cell culture lysates are 15 
shown. The gel represents three individual pull down experiments, indicated above, where 16 
the initial lysate, final wash, and elution are shown on the Coomassie stained 12% SDS-17 
PAGE. Molecular weight marker sizes are indicated to the left. The proteomic 18 
identification of the excised bands from the C. trachomatis infected HEp-2 JO146-Biotin 19 
pull down lane is indicated to the right. 20 
 21 
Fig. 5. JO146 treatment is most effective when maintained in the culture throughout the 22 
replicative and transition to EB developmental cycle phase. (A) Viable infectious yield of 23 
Chlamydia after JO146 treatments 16 h PI (compound not removed during the culture). 1 
The bars represent from left media only, DMSO, and 100 M JO146 treatment (not visible 2 
i.e. completely lethal) when harvested at 44, 54, and 64 h PI. (B) Viable infectious yield of 3 
Chlamydia after JO146 treatments 16 h PI when JO146 was washed out at 20 h PI. The 4 
cultures where harvested and viability determined at 44, 54, and 64 h PI. The bars 5 
represent (left-right): DMSO, media only, 10 M, 50 M, 100 M JO146. (C) Viable 6 
infectious yield of Chlamydia after JO146 treatments 16 h PI when JO146 was washed out 7 
at 24 h PI. The cultures where harvested and viability determined at 44, 54, and 64 h PI. 8 
The bars represent (left-right): DMSO, media only, 10 M, 50 M, 100 M JO146. The 9 
mean from three independent experiments are represented in the bar graphs and the error 10 
bars represent the standard error of the mean (n=27). (D) SDS-PAGE of the JO146-Cy5 11 
bound proteins in a lysate incubated under cell culture conditions for 4 (20 h PI) and 8 h 12 
(24 h PI). An in vitro stability assay was carried out where the JO146-Cy5 activity based 13 
probe was incubated with lysates of infected (iHEp-2), uninfected HEp-2 (Hep-2) and 14 
purified recombinant CtHtrA (CtHtrA) for 4 and 8 h (20 h and 24 h indicated below the 15 
gel). 16 
 17 
Fig. 6. JO146 treatment leads to diminishing chlamydial inclusion vacuoles. (A) 18 
Representative images of the same location in a slide culture of a C. trachomatis infection 19 
of HEp-2 cells labelled with CellTracker Blue. Treatment conditions are indicated above 20 
(JO146 100 µM) and time to the right. Arrows indicate one example inclusion vacuole for 21 
each condition. The figures have had contrast adjustment which was conducted on the 22 
whole image for each figure in the series. Representative videos are provided as Video S1. 23 
(B) Analysis of real time microscopy of JO146 treatment-impact on C. trachomatis 24 
inclusion size. (C) The number of visible inclusions in each field of view for each 1 
condition over time. The mean from three independent experiments have been calculated 2 
and are presented in the graph, the error bars represent the standard error of the mean (n = 3 
14 for the inclusion size, n = 4 for the inclusion numbers) * indicates p<0.05, ***p<0.001. 4 
An MOI of 1 was used for the experiment. 5 
 6 
Fig. 7. Confocal microscopy analysis of C. trachomatis infected HEp-2 cultures indicates 7 
inclusion size diminishes after JO146 treatment (16 h PI). (A-E) Representative images from 8 
the time of treatment (16 h PI, E), 4 h after treatment (20 h PI, C & D) and 8 h after treatment 9 
24 h PI A & B) respectively. MOMP is stained green, cell nucleus DAPI (blue), and -actin 10 
phalloidin (red). (F) Representation of the inclusion size (µm) of JO146-treated cells (black) 11 
and DMSO-treated cells (gray) at each time point, the white bar represented the untreated 12 
cells at 16 h PI. A minimum of 6 fields of view and 25 inclusions were measured at each time 13 
point and the mean of these data are indicated by the bars, the error bars indicate the standard 14 
error of the mean (n=25, *** indicates p<0.001).  (G) Viable infectious yield at various times 15 
(h PI). Light gray bars represent control cells (no DMSO and no JO146) dark gray bars 16 
represent DMSO-treated cells. Cells treated with 100 µM did not show any viable infection. 17 
The bars represent the mean of three independent experiments with the standard error of the 18 
mean indicated by the error bars (n=27). 19 
 20 
Fig. 8. Inhibitor treatment is effective in vivo using the mouse model of chlamydial infection. 21 
(A) JO146 and (B) JCP83 treatment of C. muridarum McCoy cell cultures resulted in a 22 
significant loss of viable Chlamydia. The bars represent from left to right; white: DMSO 23 
control, gray: 0 M (media only), red: 10 M inhibitor, green: 50 M inhibitor, blue: 100 M 24 
inhibitor, and yellow: 150 M inhibitor. (C) JO146 reduced shedding of viable C. muridarum 1 
from the vagina of infected mice when administered every second day during an infection. 2 
The bars on the graph represent the mean from a single experiment with the error bars 3 
indicating the standard error of the mean (6 animals, triplicate swabs from each animal at 4 
each time point were analysed n = 18). 5 
